Frontlight ResearchEarly access
Ovarian cancer trials in China
185 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in ChinaProspective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer
- Where
- Zhengzhou
- Age
- 18 years and over
- People
- 30
- Run by
- The First Affiliated Hospital of Zhengzhou University
See details and how to joinNCT07314619 - Phase 2Not yet taking people in ChinaDisitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 43
- Run by
- Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07311577 - Phase 2Taking peoplePhase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 20
- Run by
- Obstetrics & Gynecology Hospital of Fudan University
See details and how to joinNCT07261683 - Phase 3Taking peopleHS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 468
- Run by
- Hansoh BioMedical R&D Company
See details and how to joinNCT06855069 - Phase 2Taking peopleEfficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
- Where
- Zhejiang
- People
- 20
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07285941 - Phase 2Taking peopleQL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 40
- Run by
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
See details and how to joinNCT07286240 - No phaseTaking peopleSurvival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 94
- Run by
- Shanghai Gynecologic Oncology Group
See details and how to joinNCT05236686 - No phaseNot yet taking people in ChinaExploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy
- Where
- Chengdu
- Age
- 18 years to 38 years
- People
- 40
- Run by
- West China Second University Hospital
See details and how to joinNCT07201259 - Phase 1/2Taking peopleA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 38
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT05803018 - Phase 1Taking peopleStudy of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 110
- Run by
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
See details and how to joinNCT07156253 - Phase 2Not yet taking people in ChinaEtoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 33
- Run by
- Fudan University
See details and how to joinNCT07117877 - No phaseTaking peopleA Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
- Where
- Guangzhou, Shenzhen
- Age
- 18 years and over
- People
- 200
- Run by
- Sun Yat-sen University
See details and how to joinNCT06781151 - Phase 1Taking peopleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 21
- Run by
- GONGCHU Biotechnology Co., Ltd
See details and how to joinNCT06508307 - Phase 2Not yet taking people in ChinaA Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07124793 - Phase 2Not yet taking people in ChinaCombination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 37
- Run by
- Fudan University
See details and how to joinNCT07120451 - Phase 1Not yet taking people in ChinaStudy of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 105
- Run by
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
See details and how to joinNCT07088588 - Phase 1Taking peopleStudy of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
- Where
- Shanghai, Zhengzhou
- Age
- 18 years and over
- People
- 30
- Run by
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
See details and how to joinNCT06666270 - No phaseTaking peopleStudy on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Women's Hospital School Of Medicine Zhejiang University
See details and how to joinNCT06019923 - Phase 1/2Taking peopleSequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
- Where
- Beijing
- Age
- 21 years to 90 years
- People
- 80
- Run by
- Essen Biotech
See details and how to joinNCT07067255 - Phase 2Not yet taking people in ChinaEvaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer: A Single-arm Study
- Where
- Guangzhou
- Age
- 18 years to 70 years
- People
- 30
- Run by
- Jing Li
See details and how to joinNCT07068178 - Phase 2Not yet taking people in ChinaPersonalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
- Where
- Guangzhou, Shenzhen
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- The University of Hong Kong
See details and how to joinNCT07023484 - Phase 1/2Not yet taking people in ChinaSurgery for Relapsed Ovarian Cancer in Precision
- Where
- Shanghai, Wuhan
- Age
- 18 years to 80 years
- People
- 33
- Run by
- Shanghai Gynecologic Oncology Group
See details and how to joinNCT06602063 - No phaseTaking peopleDevelopment and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands
- Where
- Beijing
- Age
- 18 years and over
- People
- 10,000
- Run by
- Peking University Third Hospital
See details and how to joinNCT07039552 - Phase 1Taking peopleHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 157
- Run by
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT06769425 - Phase 3Taking peopleFluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
- Where
- Wuhan
- Age
- 18 years and over
- People
- 424
- Run by
- Tongji Hospital
See details and how to joinNCT06954584